Arslan, A.Batar, BahadırTemiz, E.Tozkır, HilmiKoyuncu, İsmailBozgeyik, Esra2022-05-112022-05-1120220301-4851https://doi.org/10.1007/s11033-022-07141-6https://hdl.handle.net/20.500.11776/4459Background: Prostate cancer is a malignant disease that severely affects the health and comfort of the male population. The long non-coding RNA TP73-AS1 has been shown to be involved in the malignant transformation of various human cancers. However, whether TP73-AS1 contributes to prostate cancer progression has not been reported yet. Accordingly, here we aimed to report the role of TP73-AS1 in the development and progression of prostate cancer and determine its relationship with TP73. Methods and results: TP73-AS1-specific siRNA oligo duplexes were used to silence TP73-AS1 in DU-145 and PC-3 cells. Results indicated that TP73-AS1 was upregulated whereas TP73 was downregulated in prostate cancer cells compared to normal prostate cells and there was a negative correlation between them. Besides, loss of function experiments of TP73-AS1 in prostate cancer cells strongly induced cellular apoptosis, interfered with the cell cycle progression, and modulated related pro- and anti-apoptotic gene expression. Colony formation and migration capacities of TP73-AS1-silenced prostate cancer cells were also found to be dramatically reduced. Conclusions: Our findings provide novel evidence that suggests a chief regulatory role for the TP73-TP73-AS1 axis in prostate cancer development and progression, suggesting that the TP73/TP73-AS1 axis can be a promising diagnostic and therapeutic target for prostate cancer. © 2022, The Author(s), under exclusive licence to Springer Nature B.V.en10.1007/s11033-022-07141-6info:eu-repo/semantics/closedAccessLncRNAProstate cancerTP73TP73-AS1ArticleQ3WOS:0007532447000022-s2.0-8512455076735138524Q2